MaaT Pharma to Host First Virtual R&D Day on June 7th, 2022
24 Mai 2022 - 6:00PM
Business Wire
- R&D Day will take place virtually on June 7th from 4:00
pm-6:00 pm (CEST)/ 3:00 pm-5:00 pm (GMT) / 10:00 am-12:00 pm
(EST)
- Event will feature expert-led discussions on the microbiome and
its potential to improve cancer therapy in hemato-oncology and
immuno-oncology
- MaaT Pharma’s management to share latest clinical data on key
assets, as well as research and manufacturing strategies aiming to
establish the Company as a leader in the microbiome industry
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French
clinical-stage biotech and a pioneer in the development of
Microbiome Ecosystem Therapies dedicated to improving survival
outcomes for patients with cancer today announced that it will
host its first R&D Day for analysts and investors to be held
virtually on Tuesday, June 7th, 2022 from 4:00 pm CEST (10:00 am
EST) to 6:00 pm CEST (12:00 pm EST).
MaaT Pharma’s speakers will discuss the microbiome's potential
in cancer therapy and the latest clinical results of MaaT013 and
MaaT033. They will also present the Company’s innovative
proprietary drug discovery platform, the next generation of
products MaaT03X and the construction of Europe’s largest cGMP
manufacturing facility for Microbiome Ecosystem Therapies.
In addition to the presentations by MaaT Pharma’s senior team,
the R&D Day will feature talks from world renowned scientists
and physicians including:
- Dr. Joël Doré – Research Director, INRAE; Scientific
Director, MetaGenoPolis and Scientific Advisor to MaaT Pharma,
France
- Prof. Ernst Holler, M.D. – Senior Professor on Clinical
and Experimental Allo-HSCT, Department of Internal Medicine,
University Hospital Center Regensburg, Germany
- Prof. Florent Malard, M.D. – Professor of Hematology,
Saint Antoine Hospital (AP-HP) and Sorbonne University
- Prof. Mohamad Mohty, M.D. – Professor, Sorbonne
University and Head of the Clinical Hematology and Cellular Therapy
Department, Saint-Antoine Hospital (AP-HP), France
- Prof. Hassane Zarour, M.D. – Professor of
Medicine, Immunology and Dermatology, University of Pittsburg,
James and Frances McGlothlin Chair in Melanoma Immunotherapy
Research
"MaaT Pharma’s inaugural R&D Day is an opportunity to bring
together world-renowned scientists and our talented internal team
to share MaaT Pharma’s innovative research and highlight our unique
positioning in the microbiome space," said Hervé Affagard, Chief
Executive Officer and Co-Founder of MaaT Pharma. "Since our
successful IPO in November 2021, we have delivered on the key
milestones we had defined and we continue to progress, with the
ambition to leverage the microbiome for the benefit of millions of
patients fighting cancer.”
A question-and-answer session will follow the presentations.
Please note that all the presentations are in English with French
subtitles. The webcast will be made available on the Company’s
website after the event.
To register for the event, please click here.
If you have any questions, please contact us at
invest@maat-pharma.com
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, a Phase 3 clinical trial for patients with acute GvHD,
following the achievement of its proof of concept in a Phase 2
trial. Its powerful discovery and analysis platform, gutPrint®,
supports the development and expansion of its pipeline by
determining novel disease targets, evaluating drug candidates, and
identifying biomarkers for microbiome-related conditions. The
company’s Microbiome Ecosystem Therapies are produced through a
standardized cGMP manufacturing and quality control process to
safely deliver the full diversity of the microbiome, in liquid and
oral formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice.
MaaT Pharma is the first company developing microbiome-based
therapies listed on Euronext Paris (ticker: MAAT).
Forward-looking Statements
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220524005862/en/
MaaT Pharma – Investor Relations Hervé AFFAGARD
Co-Founder and CEO Siân Crouzet, COO/ CFO +33 4 28 29 14 00
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 07 55 25 36
prichaud@maat-pharma.com
Trophic Communications – Corporate and Medical
Communications Jacob VERGHESE or Gretchen SCHWEITZER +49 89
2070 89831 maat@trophic.eu
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Apr 2023 bis Apr 2024